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Copyright © 2008 JCBN Summary Detection of resistance to drugs for Mycobacterium tuberculosis takes about two
months from the sample collection using culture-based methods. To test a rapid method for
detection of resistance for five antituberculosis drugs using DNA microarray and to examine
its potential for clinical use, we employed a DNA microarray for detection of seven mutations
genes related to resistance of five kinds of antituberculous drugs using Mycobacterium
tuberculosis DNA isolated from sputum. The results of microarray analysis were compared
with the results of a standard culture method of Lowenstein-jensen drug sensitivity testing
system. DNA microarray analysis showed a high sensitivity (>90%) for all five drugs.
Specificity of rifampicin and ethambutol were nearly 90%, however specificity of isoniazid
(60%) and kanamycin (67%) were not enough. The amount of Mycobacterium tuberculosis
DNA required for microarray analysis corresponded to at least 1–9 Acid-Fast Bacilli per 10
fields by carbolfuchsin staining. DNA microarray analysis appears to be useful for estimation
of drug resistances, nevertheless its limitations. To minimize misunderstanding, it is necessary
to confirm the number of bacilli in the sputum, and culture method is needed for comparison
when use the PCR-based array system.
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Introduction
The prevalence of drug-resistant tuberculosis continues to
increase around the world. According to a survey of resis-
tance to first-line antituberculous drugs performed in 1994
by the World Health Organization and the International
Union Against Tuberculosis and Lung Disease, multi drug-
resistant tuberculosis (MDR-TB) was found in all 35
countries investigated. In 2000, MDR-TB was detected in 72
countries, and MDR-TB was also serious problem on
immuno-compromised host [1]. With current methods based
on culture, it takes about two months after collection of
sputum to obtain the result of drug resistance test, i.e. after
sample collection, the tuberculosis organisms needed to
growth in culture, and then, the part of organisms grown onDrug Resistances Detection of Mycobacterium tuberculosis
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its culture are put on another drug sensitivity test culture. At
the start of therapy, empirical therapy with several anti-
tuberculous drugs are needed, and if failed to cure due to
drug resistance of TB, the duration of hospitalization would
be quite long. Therefore, it would be beneficial to treat
drugs resistant-TB more effectively. In particular, the rapid
detection of drug resistance would be expected to over-
coming this problem. Several new technologies have been
developed for the rapid assessment of drug resistance using
high density DNA probe [2], solid-phase sequence scanning
[3] and invader assay using real-time PCR [4]. Although
these methods have proven effective, these method need for
an expensive microarray scanner to detect fluorescence, or
sequencer. The INNO-LiPA Rif. TB® (LiPA) is a commercial
line probe assay using nitrocellulose paper strips, and
adapted to clinical setting in developed countries [5]. This
system is used for detect genetic mutation in the rpoB gene
region related to Rifampicin (RFP) resistance. There is no
method for simultaneously rapid detection of five kinds of
antituberculosis drug resistances in practical medicine. Also,
the current rapid diagnosis systems have not yet become
widely available, and the rapid detection of drug resistances
remains a major public health problem.
From the study of M. tuberculosis DNA, it has become
clear that missense mutations play a role in drug resistance.
Mutations of the inhA [6] and KatG [7] genes of M. tubercu-
losis are involved in about 80% of resistance to isoniazid
(INH), mutations of the rpoB gene control about 95% of
resistance to rifampicin (RFP) [8], mutations of the rrs and
rpsL genes are concerned with about 80% of resistance to
streptomycin (SM), mutations of the rrs gene cause 70% of
resistance to kanamycin (KM), and mutations of the embB
gene produce about 70% of resistance to ethambutol (EB)
[9]. On the basis these seven genes related to antituberculous
drug resistance, we developed a DNA microarray that could
detect mutations of all seven genes rapidly in one day and
simply. Array signals were obtained by a peroxidase reac-
tion, and were detected easily using an office scanner, as
previously reported [10]. There have been no reports about
detection of resistance to five antituberculous drugs at once.
In this study, we tested the DNA microarray for detection
of mutations of the seven genes mediating resistance to the
above-mentioned five drugs using M. tuberculosis DNA iso-
lated from sputum. The results of microarray analysis were
compared with the drug resistance data obtained using
culture method, and we assessed the accuracy of detecting of
drug resistance with the microarray, and also we try to clarify
the limitations of DNA microarray use in clinical setting.
Method
Sample collection and extraction of M. tuberculosis DNA
Sputum samples (n = 48) were obtained from 48 tubercu-
losis patients with pulmonary tuberculosis. The diagnosis of
M. tuberculosis infection was based on radiography, smear
of sputum, and PCR using the Amplicore method for M.
tuberculosis (Roche Diagnostic Systems, Somerville, NJ),
and culture-based method of Lowenstein-jensen standard
culture-based drug sensitivity testing system raised in
recommended drug concentrations for drug susceptibility
testing as described [11]. Sputum samples were homogenized
with semi-alkaline proteinase (Sputazyme, Kyokuto Pharma-
ceutical, Co. Ltd., Japan) according to the manufacturer’s
instructions. Homogenized sputum was treated by the
NALC-NaOH method [11], and then DNA was isolated
using a specimen preparation kit (COBAS AMPLICORETM,
Roche Diagnostics, NJ). This study was conducted
according to the Declaration of Helsinki, and all patients
gave written informed consent before enrollment, and was
approved by the Human Research Committee of Gunma
University.
DNA amplification
Fragments of drug resistance-related genes (rpoB, inhA,
katG, rpsL, rrs, and emb B) containing drug-sensitive or
drug-resistant polymorphisms were amplified by multiplex
PCR using 18 sets of primers. The rrs gene was also
amplified in the same tube to distinguish M. tuberculosis
from M. avium. The target genes, amplicon sizes, and primer
sequences are listed in Table 1a, and the relationship
between target gene, primer, and mutation site is shown in
Table 1b. These 18 primers detect known mutations in the
followings of the rpoB, inhA, katG, rpsL, rrs, and emb B
genes (Table 2). PCR amplification was performed by the
following procedure. The reaction mixture (19 µl) contained
10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 200 nM of each
dNTP, 500 nM of each primer, 2.5 U of AmpliTaq Gold
(Applied Biosystems Japan Ltd., Japan), and 1 µl of
genomic DNA. The reaction mixture was preheated at 95°C
for 9 min, followed by 50 cycles of denaturation at 94°C for
30 s, annealing and extension at 64°C for 1 min, with post-
cycling extension at 72°C for 10 min using a DNA engine
thermal cycler (MJ Research Inc., Waltham, MA).
DNA microarray
DNA oligomers about 20 to 24 bp long were immobilized
on glass slides [10]. The arrangement of mutation detection
sites on the DNA microarray is shown in Table 1c. The
microarray field was largely divided into isoniazid (INH),
RFP, SM, KM, and EB resistance detection fields, as well as
a M. tuberculosis and M. avium complex detection field.
The oligomers spotted in the extreme left hand lane
contained the wild-type DNA sequences, while the other
lanes contained the mutants. If there was no signal in the
M. tuberculosis detection field, the sample did not contain
M. tuberculosis and the test was invalid even if positiveY. Shimizu et al.
J. Clin. Biochem. Nutr.
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signals were detected in the drug resistance fields. If the
wild-type oligomer did not show a signal and mutants
yielded signals on the DNA microarray, drug resistance was
diagnosed.
Hybridization and signal detection
The PCR product (5 µl) was mixed with 20 µl of hybrid-
ization solution, and then the mixture was denatured at 98°C
for 5 min and chilled on ice for 1 min before being used as
biotin-labeled DNA probes. Subsequently, the mixture was
Table 1a. Forward and Reverse Primers for Drug Resistance Genes.
amplicon size target gene primer forward primer sequence (5'-3') primer reverse primer sequence (5'-3')
71 bp inhA 1F CGT GGA CAT ACC GAT TTC G 1R 5'biotin-TCA GTG GCT GTG GCA GTC A
186 bp KatG 2F GGT CGC GAC CAT CGA CGT TG 2R 5'biotin-AAC CGC TGC ATG CCG C
79 bp KatG 3F GCT TAA CAG CAG GCC CGA C 3R 5'biotin-CTT GCC GTA CTT CTT CTT GAC C
142 bp KatG 4F GGT CAA GAA GAA GTA CGG CAA G 4R 5'biotin-AAT AgA CCT CAT Cgg gCT C
50 bp KatG 5F GCG GTC ACA CTT TCG GTA 5R 5'biotin-GAC CAG ATC GGC CGG G
119 bp KatG 6F AAG AGC TCG TAT GGC ACC 6R 5'biotin-TCG CCG TAC AGG ATC T
102 bp KatG 7F GCC GAG ATT GCC AGC CTT 7R 5'biotin-GCT ACC ACG GAA CGA CGA
93 bp KatG 8F GAA TCC TTT GCC GTG CTG GAG  8R 5'biotin-GTC GAG CAG CAT GTA CTC
158 bp negative control 9F CTC TTC GGA GAT ACT CGA GTG 9R 5'biotin-CCG CGG GCT CAT CCC AC
124 bp rpoB 10F GCC GCG ATC AAG GAG TTC 10R 5'biotin-CAC GTG ACA GAC CGC CGG
153 bp rrs 11F GGT TCT CTC GGA TTG ACG GTA G 11R 5'biotin-AGC CGT GAG ATT TCA CGA ACA AC
99 bp rrs 12F GGT TTC CTT CCT TGG GAT C 12R 5'biotin-GGC CCC CGT CAA TTC CTT
63 bp rpsL 13F TAT GCA CCC GCG TGT ACA 13R 5'biotin-GGG CAA CCT TCC GAA GCG
106 bp rpsL 14F GAG GTC ACG GCG TAC ATT 14R 5'biotin-TCT TGT AGC GCA CAC CAG
65 bp rrs 15F CTT GTA CAC ACC GCC CGT 15R 5'biotin-CGA GGG TTA GGC CAC TGG
76 bp rrs 16F CCA GTG GCC TAA CCC TCG 16R 5'biotin-CGG CTA CCT TGT TAC GAC
92 bp embB 17F GTG GTG ATA TTC GGC TTC CT 17R 5'biotin-TGG TCG GCG ACT CGG GC
80 bp embB 18F CAA CTA TTT CCG CTG GTT CG 18R 5'biotin-TGA CAT GGG TCA TCA GCG
Drug resistance genes were inhA and KatG (INH), rpoB (RFP), rrs and rpsL (SM), rrs (KM), and embB (EB).
Table 1b. Relations between Primer Numbers, Drug Resistance Genes and Mutation Sites.
primer target gene mutation
1 inhA 1022A/G, 1023C/T, 1030T/A, 1030T/G
2 KatG 281A/C, 322, 324CC/GG, 369G/C
3 KatG 412A/C, 413A/G, 419G/A, 425A/C
4 KatG 479C/T, 514G/A, 539C/A
5 KatG 823A/G
6 KatG 944G/A, 944G/C, 944, 945GC/CA, 982T/G
7 KatG 1431G/A
8 KatG 1778G/A
9 negative control —
10 rpoB 180C/A, 180C/G, 180C/T, 181A/C, 190A/T, 191C/A, 201C/T, 208C/T, 218, 220, 222CAA/GCC, 219C/
A, 219C/G, 219C/T, 220A/C, 220A/G, 221C/A, 221C/G, 235C/G, 235C/T, 241T/C
11 rrs 505C/T, 526C/T, 527A/C, 527A/T, 530C/T
12 rrs 920C/A, 920C/G, 921A/G, 893G/A
13 rpsL 134A/G, 134A/C
14 rpsL 269A/C, 269A/G, 269A/T
15 rrs 1423A/G, 1424C/A, 1424C/T
16 rrs 1516G/T
17 embB 7868A/G, 7868A/C, 7870G/A, 7870G/T, 7870G/C
18 embB 7940T/G
Drug resistance genes were inhA and KatG (INH), rpoB (RFP), rrs and rpsL (SM), rrs (KM), and embB (EB).Drug Resistances Detection of Mycobacterium tuberculosis
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applied to a DNA microarray slide, covered with a coverslip,
and hybridized at 42°C for 60 min. After hybridization, the
DNA microarray was washed in washing buffer A at 42°C
for 20 min to remove excess biotin-labeled DNA probes.
Hybridization signals were developed as black spots by
the peroxidase method. The binding solution (1.4 ml) was
prepared from a kit according to the manufacturer’s instruc-
tions, and was applied to the oligonucleotide spots on the
DNA microarray, after which the microarray was incubated
for 30 min at room temperature. Then the slide was washed
twice with the coloring buffer for 5 min at room tempera-
ture. Next, 1.4 ml of coloring solution was prepared from
the same kit according to the manufacturer’s instructions,
drops of the solution were added to the DNA microarray,
and incubation was done at room temperature for 30 min.
Subsequently, the microarray was rinsed with distilled water
and air-dried. All of the solutions and buffers for hybridi-
zation were supplied by Nisshinbo Industries, Inc. Black
hybridization signals on the microarray were scanned using
a standard OA scanner (GT-8700F, Epson, Tokyo, Japan) to
provide signal intensity data for subsequent computer anal-
ysis.
Drug sensitivity test using broth culture
Homogenized sputum was treated with NALC-NaOH
[12], and then inoculated into a Lowenstein-jensen standard
culture-based drug sensitivity testing system raised in
recommended drug concentrations for drug susceptibility
testing as described [8] according to the manufacturer’s
instructions (Mycosensitive spectrum-SR, Kyokuto, Tokyo,
Table 1c. Arrangements on Microarray for Drug Resistance Genes
B W 1022A/G 1023C/T INH B B W 180C/A 180C/G 180C/T 181A/C RFP B
W 1030T/A 1030T/G W 190A/T 191C/A
W 281A/C W 201C/T
W 322,324 W 208C/T
CC/GG
W 369G/C W 218, 220, 222 219C/A 219C/G 219C/T 220A/G 220A/G 221C/A 221C/G
CAA/GCC
W 412A/C 413A/G 419G/A W 234C/G 234C/T 240T/C
W 425A/C B W 505C/T SM B
W 479C/T W 526C/T 527A/C 527A/T 530C/T
W 514G/A W 920C/A 920C/G 921A/G
W 539C/A W 893G/A
W 823A/G W 134A/G 134A/C
W 944G/A 944G/C 944, 945 W 268A/C 269A/C 269A/T
GC/CA
W 982T/G B W 1423A/G 1424C/A 1424C/T KM B
W 1431G/A W 1516G/T
W 1700T/C B W 7868A/G 7868A/C 7870G/A 7870G/T 7870G/C EB B
W 1778G/A B W 7940T/G B
B Tub-P Tub-N avi-P avi-N acid-fast B
Drug resistance genes were inhA and KatG (INH), rpoB (RFP), rrs and rpsL (SM), rrs (KM), and embB (EB). Tub-p, Tub-N, Avi-P and
Avi-N indicates tuberculosis positive, negative, avidin positive, negative. Acid-fast indicates non-tuberculosis of acid fast. The site of B
indicates position marker of each drugs mutation detection field on array. The microarray field is devided into INH, RFP, SM, KM, and
EB resistance detection fields. When there are positive signal in the Tub-P and Avi-P spots, the sample contains M. tuberculosis and the
DNA microarray test is valid.
Table 2. Antituberculous Drug Resistance Genes and the Role of them in the Resistance of M. tuberculosis.
Oligomers on the DNA microarray were arranged to detect all mutations of rpoB, inhA, KatG, rrs, rpsL, rrs, and emb B.
anti-TB drug Drug resistance-related genes
Importance of each gene 
in anti-TB drug resistance
DNA microarray coverage 
of resistance genes
INH inhA, katG 80% 100%
RFP rpoB 95% 100%
SM rrs, rpsLL 80% 100%
KM rrs 70% 100%
EB embB 70% 100%Y. Shimizu et al.
J. Clin. Biochem. Nutr.
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Japan). The cut-off values for each drug were as follows:
INH (0.2 µg/ml), RFP (40.0 µg/ml), SM (10 µg/ml), KM
(20 µg/ml), and EB (2.5 µg/ml) [11]. The result of drug
resistant patient’s number based on culture method were
followings (wild/mutant); INH (38/10), RFP (28/20), SM
(40/8), KM (44/4) and EB (39/9).
Grading of sputum smears
To grade the quantity of M. tuberculosis bacilli in sputum
smears, carbolfuchsin staining was performed. Stained
smears were examined by microscopy (Olympus BX50F4)
of high power field (HPF) of ×200, and scored according to
the quantitation scale for AFB smears. Criteria for grading
the quantity of M. tuberculosis bacilli were according to the
method reported in the official statement of the ATS and
CDC [11].
Amplification of H37Rv M. tuberculosis DNA
DNA from the laboratory strain M. tuberculosis H37Rv
was isolated using phenol-chloroform and ethanol, and was
employed as the positive control on gel electrophoresis.
M. tuberculosis DNA from sputum samples and H37Rv
was diluted (1, 10, 100, 1000, 10000, 10000) in TE buffer,
and the 85A gene (a M. tuberculosis-specific gene) was
amplified by PCR. The PCR master mix contained 2 µl of
10 × PCR buffer with 15 mM MgCl2, 1.6 µl of 2.0 mM
dNTP, 2 µl of 25 mM MgCl2, 7.6 µl of distilled water, and
0.2 µl of AmpliTaqGold. Then 1 µl of HRv37 DNA was
added, as well as 100 pmol of the primers for the 85A gene
(U; 5' CCGCGGGGGCATTTTC 3', L; 5' GCTCCCGCG-
TAGACGAACT 3'), and amplification was done. PCR
started with denaturation for 9 min at 95°C, followed by 50
cycles of 30 s at 94°C and 1 min at 64°C, as well as 10 min
at 72°C for extension using an ABI prism 3300 (PE
Biosystems Ltd.).
Statistical analysis
The accuracy of the DNA microarray for detecting
resistance was calculated from the sensitivity (true positive
rate) and specificity (true negative rate) of 95% confidence
intervals (CI). Specimens that were positive by both methods
were defined as true positive and specimens negative by
both methods were defined as true negative.
Results
The drug resistances of M. tuberculosis isolated from
sputum samples were evaluated by culture-based method of
Lowenstein-jensen drug sensitivity testing system and DNA
microarray analysis, and both results were compared. DNA
microarray analysis of resistance to RFP, SM, and KM is
shown in Figure 1a and 1b. The test was performed on 48
samples, and the result of the sensitivity of DNA microarray
diagnosis was high (>90%) for all five antituberculous
drugs. The specificity for RFP and EB was also high, being
>95.0% and 89.0%, respectively, by DNA microarray
diagnosis. However, specificity for INH, SM, and KM
was only 60.0%, 73.0%, and 67.0%, respectively.
To investigate the reasons for the discrepancy between
culture-based and DNA microarray methods, we performed
sequencing of sputum DNA samples. Sequence analysis was
performed as previously [10]. Mutant type by DNA micro-
array analysis on sputum sample showed mutant by sequence
analysis (data not shown). Colonies samples from these
sputum samples showed wild type by cultured-based drug
resistance test. In addition, we harvested the colonies grown
in culture of the sputum specimens, and purified DNA from
those colonies was subjected to DNA microarray analysis.
When the colonies samples were used for DNA microarray
after cultured (i.e., not sputum), the result of culture based
method and DNA microarray analysis were corresponded.
Thus, after growth on culture, microarray analysis of
colonies were corresponded with the culture-based method,
appeared that the bacteria were supposed to be hetero-
geneous from those in the sputum as described [13].
Among the specimens that were mutant by the culture-
based method but wild-type by microarray analysis, there
were several samples with a low number of acid-fast bacilli
(AFB) on smears of less than 1-9 AFB per 100 fields using
carbolfuchsin stain. To determine the limit of detection by
Table 3. Sensitivity and Specificity of DNA Microarray Analysis in M. tuberculosis Sputum Sample.
The sensitivity and specificity were calculated by assuming that the culture-based method of Lowenstein-jensen drug
sensitivity test was correct. The number of samples tested for each drug (wild/mutant) was as follows: INH (38/10), RFP
(28/20), SM (40/8), KM (44/4), and EB (39/9).
anti-TB drug sensitivity (95% CI) specificity (95% CI)
INH 0.91 (0.77–0.97) 0.60 (0.30–0.88)
RFP 0.97 (0.82–1.0) 0.95 (0.75–1.0)
SM 0.93 (0.80–1.0) 0.73 (0.4–0.94)
KM 0.96 (0.85–1.0) 0.67 (0.22–1.0)
EB 0.98 (0.87–1.0) 0.89 (0.52–1.0)Drug Resistances Detection of Mycobacterium tuberculosis
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DNA microarray analysis for smear grades, we performed
PCR for the 85A gene of M. tuberculosis obtained from
sputum samples and the pure genome of H37Rv M. tubercu-
losis strain. A PCR for the 85A gene showed that the limit of
DNA microarray analysis was 10-20 AFB per 100 fields in
sputum samples including AFB and 104 bacilli for the
H37Rv genome. These results showed that at least 1-9 AFB
per 10 fields on carbofuchsin staining was needed.
Discussion
The present study revealed that a DNA microarray
method showed good sensitivity in five drugs of INH, RFP,
SM, KM and EB (> 90%) and specificity in RFP (95%) and
EB (89%) for distinguishing wild-type from mutant M.
tuberculosis in patient sputum samples. Signals on the DNA
microarray could be easily viewed with an office scanner,
however, at least 1-9 AFB (i.e., M. tuberculosis bacilli) per
10 fields on carbolfuchsin staining of amount of bacilli were
needed to prevent misunderstandings in microarray.
There were several possible reasons for the difference in
results between the culture-based method and the DNA
microarray. DNA microarray could detect mutant correctly,
when the M. tuberculosis DNA after growing in culture
was applied to DNA microarry, that is, the results of drug
resistant analyzed by culture-based method and the result of
DNA microarry was corresponded in analysis from the
M. tuberculosis DNA after growing in culture. However, in
several M. tuberculosis DNA samples isolated from sputum,
the results of drug resistant analyzed by culture-based
method and the result of DNA microarray were not
corresponded. Possible reason was reported that hetero-
geneity of resistance in sputum sample could be affected
the discrepancy between culture-based method and DNA
microarray analysis [13]. The meta-analysis of accuracy of
LiPA showed that LiPA was a highly sensitive and specific
test for the detection of RIF resistances in culture isolates.
However, the test was also reported that it appeared to have
lower sensitivity when used directly on clinical specimens
as our DNA microarray [5]. Prediction of drug-resistant
genotypes of mycobacterium found after cultivation not
always give a good reflection of those in the original clinical
sample. Further analysis was needed whether this matter
occurred or not in our study. From the analysis of present
study of needed amount of M. tuberculosis bacilli using
H37Rv genome and sputum sample genome from M.
tuberculosis patients, to minimize misunderstandings in
microarray, we found that at least 1-9 AFB (i.e., M.
tuberculosis bacilli) per 10 fields on carbofuchsin staining
were needed to in our microarray analysis. There was
another possible reason for the culture-based method
showing mutant DNA and the microarray showing the wild-
type. Present DNA microarray was not prepared with
primers and spots for mutations of KasA and ahpC (INH) or
embA and embC (EB) [9]. If M. tuberculosis contained these
genes, they would not be amplified by PCR of DNA directly
isolated from sputum, and these genes would confer resis-
tance in the culture-based method. This specimen possibly
Fig. 1. a. Explanation of the DNA microarray. The array was divided into six fields. Black circles are position markers for biotinylated
oligomers in each fields. Double circles are wild-type and single circles are mutant. b. The result of DNA microarray analysis of
sputum with RFP, SM, and KM resistance.Y. Shimizu et al.
J. Clin. Biochem. Nutr.
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shows mutant by the cultured-based method, nevertheless
wild-type by the DNA microarray method. To improve
specificity, it will be necessary to devise suitable primers
and add spots for these genes to the DNA microarray in the
future.
Taken together, to minimize misunderstandings on DNA
microarray, it will be necessary to obtain bacteria equivalent
to at least 1-9 AFB per 10 fields on carblofuchsin staining, as
well as using the culture-based method for confirmation.
In conclusion, drug resistance genes detection using DNA
microarray appeared to be useful, however, direct applica-
tion of M. tuberculosis DNA from the sputum to DNA
microarray has a risk of misdiagnosis. It is thus necessary to
carefully select the conditions for use of such methods.
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